Correlates of response to Olanzapine in a North Indian Schizophrenia sample

Abstract Olanzapine is widely used for the treatment of schizophrenia and is considered a first line medication in India. Along with other factors, the variation in response and side effects to this agent may be accounted for by genetic differences among patients. Olanzapine was administered for 6 w...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2008-12, Vol.161 (3), p.275-283
Main Authors: Thomas, Pramod, Srivastava, Vibhuti, Singh, Anuradha, Mathur, Priya, Nimgaonkar, Vishwajit L, Lerer, Bernard, Thelma, B.K, Deshpande, Smita N
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Benzodiazepines - adverse effects
Benzodiazepines - therapeutic use
Biological and medical sciences
Body Weight - drug effects
Chromosome Deletion
Developing Countries
Dopaminergic genes
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug-metabolizing enzymes
Female
Humans
India
Male
Medical sciences
Middle Aged
Neuropharmacology
Olanzapine
Pharmacology. Drug treatments
Polymorphism, Genetic - genetics
Psychiatric Status Rating Scales
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Risk Factors
Schizoaffective
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - genetics
Schizophrenic Psychology
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Olanzapine is widely used for the treatment of schizophrenia and is considered a first line medication in India. Along with other factors, the variation in response and side effects to this agent may be accounted for by genetic differences among patients. Olanzapine was administered for 6 weeks to Indian subjects with schizophrenia or schizoaffective disorder (DSM-IV, n = 130), as part of an open label study. Intent-to-treat analysis was performed, and 10 polymorphic markers from seven genes (dopamine D1, D2, D3 and D4 receptors, serotonin 2A receptor and the drug-metabolizing enzymes (CYP1A2 and CYP2D6)), together with demographic and clinical variables, were analyzed as potential predictors of response. Olanzapine was efficacious, but significant weight gain was noted. Baseline weight and a 120 bp deletion polymorphism at the dopamine receptor D4 ( DRD4 ) gene were associated with changes in symptom scores. Predictable covariates of treatment response were also noted. These results merit replicate studies.
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2007.09.010